Indomethacin

Indomethacin

Cat. No.: PI53861

Description: Indomethacin is NSAID with anti-inflammatory, analgesic, and antipyretic properties. It is a synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. Indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survival, which may result in tumor cell apoptosis.

Indomethacin
Product Details
CAS 53-86-1
Molecular Formula C19H16ClNO4
Molecular Weight 357.8
Standard BP / EP / IP / USP
Uses Oral indomethacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, and acute painful shoulder (bursitis and/or tendinitis), and acute gouty arthritis. Intravenous indomethacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours of usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.
Mechanism Of Action The anti-inflammatory, analgesic, and antipyretic effects of indomethacin and other NSAIDs, including selective inhibitors of cyclooxygenase-2 (COX-2) (e.g., celecoxib), appear to result from the inhibition of prostaglandin synthesis. While the precise mechanism of the anti-inflammatory and analgesic effects of NSAIDs continues to be investigated, these effects appear to be mediated principally through inhibition of the COX-2 isoenzyme at sites of inflammation with subsequent reduction in the synthesis of certain prostaglandins from their arachidonic acid precursors. This effect may be related to the inhibition of the synthesis of prostaglandins that are believed to play a role in modulating the rate and extent of leukocyte infiltration during inflammation. Indomethacin also inhibits lysosomal enzyme release from polymorphonuclear leukocytes.

* Our products are for research use only.

Get in Touch

We’re glad to help you with your products and services demands. For any inquiry, question or recommendation, please send an email to or fill out the following form.

Verification code
For product and service inquiries icon1

For product and service inquiries, please use our online system or send an email to .

For product and service inquiries icon2